<div>
  <ul>
    <li>
      <p>
        Integrated Biosciences, a biotechnology company specialized in using synthetic biology and ML to develop therapeutics for age-related diseases, and patient-focused Project 8p Foundation have formed a strategic partnership aimed at developing treatments for chromosome 8p duplication, deletion, and inverted duplication deletion (inv/dup/del) disorders. The terms and financial details of the agreement have not been disclosed.
      </p>
    </li>
    <li>
      <p>
        The partnership will support Project 8p Foundation, which will enable Integrated Biosciences to characterize and correct the dysregulation of cellular stress responses in 8p cell lines, leading to the development of disease-modifying treatments for 8p patients suffering from complex rearrangements of the short arm of chromosome 8p.&nbsp;
      </p>
    </li>
    <li>
      <p>
        Integrated Biosciences specializes in synthetic biology and AI to develop novel therapeutics targeting age-related diseases. Leveraging proprietary technology, Integrated Biosciences focuses on controlling cellular stress responses, which are critical in conditions like neurodegeneration, cancer, and diabetes.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20240423492950/en/Integrated-Biosciences-Partners-with-Project-8p-Foundation-to-Pioneer-a-New-Path-to-Groundbreaking-Treatments-for-Chromosomal-Disorders">
      <b>Press release</b>
    </a>
  </p>
  <p>
  </p>
</div>


Longevity Tech

PROMINENT_CATEGORY

<div>
 <p>Integrated Biosciences, a biotechnology firm with expertise in synthetic biology and machine learning (ML), has partnered with Project 8p Foundation to develop therapeutics for chromosome 8p disorders. The partnership will assist Project 8p Foundation in characterizing and correcting cellular stress response dysregulation in 8p cell lines, which could lead to new treatments for patients suffering from complex modifications of the chromosome 8p's short arm. Integrated Biosciences, which uses its proprietary technology to control cellular stress responses in conditions like neurodegeneration, cancer, and diabetes, hasn't revealed the financial terms and details of the partnership. </p>   
</div>

Integrated Biosciences and Project 8p Foundation partner to advance treatment for chromosomal disorders

INCUMBENTS_PRESENT

<div>

<p>Oura, a health tracking smart ring manufacturer, has formed a partnership with American retail company Target to retail its wearable technology in stores and online. The partnership makes Oura's smart rings readily available in Target stores and provides in-store sizing experiences for customers. Additionally, they offer an online purchase option of a sizing kit priced at USD 10. This comes with a gift certificate to reimburse the initial expense.</p>

</div>

Oura partners with Target to sell smart rings in-store and online

ANALYST_QUICK_TAKE

<div>
 
 <p>Rubedo Life Sciences has raised USD 40 million in Series A funding, led by Khosla Ventures and Ahren Innovation Capital. Other participants include Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, and Italian Angels for Growth (IAG). This brings the total funds raised by the company to USD 53.5 million.</p>
 <p>The company plans to use the investment to take its lead therapeutic candidate, RLS-1496, into Phase 1 trials for chronic atopic dermatitis and chronic psoriasis.</p>
 <p>Rubedo Life Sciences, based in California, is a biopharmaceutical firm. It focuses on creating new ways to target senescent cells that contribute to age-related diseases. Using its Alembic drug discovery platform, the firm has identified druggable targets for therapeutic development aimed primarily at combating age-related pathologies.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Prior to this, in February 2023, the company received USD 1.45 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to support the R&amp;D of a pharmacological regenerative treatment of idiopathic pulmonary fibrosis targeting senescent lung stem cells.</p>

Rubedo Life Sciences raises USD 40 million in Series A funding to support the clinical trials of lead candidate RLS-1496

<div>
 <p>Movano Health, a company specializing in passive remote monitoring, has garnered USD 24 million through a private placement consisting of 45 million units. The funding round had participation from a top-level medical device firm, along with the Movano Health's management and board of directors, which increases the company's total funds to USD 59.7 million.</p>
 <p>This new capital will serve to fund operational expenses and be distributed to other general business necessities. The earnings, combined with the company's existing financial standing, are anticipated to support the company's functioning plan until 2025.</p>
 
</div>

Movano Health raises USD 24 million via private placement for operational expenses

<div>
 <p>British biotech company, Mission Therapeutics, has successfully raised GBP 25.2 million (USD 32.1 million) in venture funding. The investment round was co-led by Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital, all of whom are existing investors.</p>
 <p>These funds will be used to develop the company's primary drug candidates, MTX325 and MTX652. Both drugs target a mitochondrial de-ubiquitylating enzyme (DUB) called USP30. By enhancing damage-associated mitochondrial ubiquitylation, they aid mitophagy - a key process that cells use to eliminate dysfunctional mitochondria.</p>
 <p>Mission Therapeutics, based in the United Kingdom, utilises this principle in their work on treatments for diseases such as Parkinson's. The focus is on boosting the mitophagy process, critical in removing dysfunctional mitochondria from our cells. There is a body of scientific evidence suggesting that the accumulation of dysfunctional mitochondria within cells is connected to a range of diseases. These include Parkinson's disease, kidney disease, heart failure, and Duchenne's muscular dystrophy.</p>
</div>

Mission Therapeutics raises GBP 25.2 million in venture funding to support clinical development of drug candidates MTX325 and MTX652

<div>
 <p>Longevity diagnostic firm GlycanAge, headquartered in the UK, has secured EUR 3.9 million (USD 4.2 million) in a seed funding round. The round was jointly led by LAUNCHub Ventures and Kadmos Capital.</p>
 <p>This funding will be allocated to transition from the longevity sector to the broader diagnostics market. It will aid in the creation of disease-specific prognostic biomarkers and assist in establishing a definitive regulatory strategy and product pipeline.</p>
</div>

GlycanAge raises EUR 3.9 million in seed funding to enter broader diagnostic market

<div>
 <p>Pharmaceutical company BioAge Labs has collected a funding of USD 170 million in a series D round that was oversubscribed. The funding round was led by Sofinnova Investments, and was participated in by both new investors such as Longitude Capital, RA Capital and Cormorant Asset Management, and existing investor Andreessen Horowitz.</p>
 <p>The company aims to utilize this funding for progressing towards the Phase II clinical development of its primary compound, azelaprag. This drug is being developed for obesity treatment. The clinical trials for the same are scheduled to commence in mid-2024, and will be done in collaboration with Eli Lilly's Chorus organization.</p>
 
</div>

BioAge Labs raises USD 170 million in oversubscribed Series D funding for clinical development

<div>
 
 <p>Lineage Cell Therapeutics has announced an agreement with investors for the purchase and sale of 13,461,540 shares at USD 1.04 per share in a direct registered offering. The offering is scheduled to close on February 8, 2024, depending on the fulfilment of stipulated closing conditions. Board members Neal Bradsher of Broadwood Partner and Don M. Bailey have agreed to purchase 6,730,770 and ~100,000 shares respectively. The expected gross proceeds from the offer will total USD 14 million.</p>
 <p>Lineage expects to use the proceeds for general corporate purposes, including clinical trials, R&amp;D, general and administrative expenses, and working capital.</p>
 
</div>

Lineage Cell Therapeutics announces USD 14 million registered direct offering for general corporate purposes

<div>
<p>Diagnostics and lifestyle company AgeCurve has received an investment of GBP 250,000 (~USD 313,460) from a Central European investment firm. These funds will be directed towards developing a licensable Cell Tree Rings product for the aging diagnostics industry, along with advancing in aging therapeutics and cell therapy.</p>  
</div>

AgeCurve raises GBP 250,000 to develop licensable Cell Tree Rings product for aging diagnostics sector

<div>
 
 <p>Our Ring, a diagnostics and lifestyle product provider, has unveiled a new aspect known as the 'resilience feature'. This function is designed to assist in stress management by building mental strength and enhancing recovery after stressful conditions. The newly introduced feature will be a part of the existing Oura Ring products.</p>
 <p>This 'resilience feature' is targeted at evaluating a user's ability to cope with physiological stress using data related to daytime stress load and recovery rates. It allows users to monitor their daily levels of stress and track progress in recovery, with the results being available for viewing on their homepage by the evening.&nbsp;</p>
 
</div>

All Updates